Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer

Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer

US Patent 10138479 · Granted Nov 27, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CDCP1 antibodies and antibody drug conjugates2025
Combination therapy for PI3K-associated disease or disorder2025
Targeting chromosomal instability and downstream cytosolic DNA signaling for can2023
Directed differentiation of oligodendrocyte precursor cells to a myelinating cel2022
Methods for treating cancer resistant to ErbB therapeutics2021
Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-asso2020
Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-asso2020
Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-asso2020
Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-asso2020
Directed differentiation of oligodendrocyte precursor cells to a myelinating cel2020
Directed differentiation of oligodendrocyte precursor cells to a myelinating cel2019
Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereof2019